GlassScriptPhysician profile
Marjan Vandevar
NPI 1861759862
$4,593.13
in general payments reported to CMS, 2019-2025
27 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.53 · 2021: $18.31 · 2022: $313 · 2023: $1,859 · 2024: $1,197 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.25 |
| Education | $168.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $652.41 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $481.09 | 2022-2025 | Jynarque |
| Shield Therapeutics INC | $354.98 | 2023-2025 | Accrufer |
| Opko Pharmaceuticals, LLC | $331.35 | 2022-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $293.22 | 2022-2025 | Farxiga |
| Vifor Pharma, INC. | $277.32 | 2020-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $261.41 | 2023-2025 | |
| Amgen INC. | $260.81 | 2024-2025 | Krystexxa, Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $239.37 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $233.86 | 2022-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $191.83 | 2023-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $191.06 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $190.46 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $110.64 | 2024 | Velphoro, Korsuva |
| Ardelyx, INC. | $98.49 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $69.35 | 2023-2024 | Crysvita |
| Akebia Therapeutics INC | $49.99 | 2024 | Auryxia, Vafseo |
| Renalytix Ai, INC. | $47.20 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $46.89 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $42.76 | 2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $42.39 | 2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $30.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.40 | 2025 | Keveyis |
| Abbott Laboratories | $18.52 | 2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $18.26 | 2022 | |
| Cormedix INC. | $17.91 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjan Vandevar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.